Physician profile
Carl Silberman
NPI 1407906696
$1,068.55
in general payments reported to CMS, 2019-2025
18 companies · $177 in 2025
The $177 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.18 · 2020: $77.38 · 2021: $98.19 · 2022: $394 · 2023: $144 · 2024: $122 · 2025: $177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $293.76 | 2021-2024 | Linzess, Viberzi, Creon |
| Amgen INC. | $250.94 | 2021-2025 | Evenity, Enbrel, Otezla |
| Ucb, INC. | $134.91 | 2022-2025 | Bimzelx, Cimzia |
| Novo Nordisk INC | $60.88 | 2020 | |
| Aurinia Pharma U.S., INC. | $46.33 | 2025 | Lupkynis |
| Glaxosmithkline, LLC. | $37.01 | 2022 | |
| Abbott Laboratories | $35.99 | 2023-2025 | Freestyle Libre 3 |
| Janssen Biotech, INC. | $31.11 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.04 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $22.10 | 2023 | Jardiance |
| Esperion Therapeutics, INC. | $20.36 | 2022 | |
| Alexion Pharmaceuticals, INC. | $17.89 | 2024 | Strensiq |
| Kowa Pharmaceuticals America, INC. | $16.50 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.75 | 2019 | |
| Merck Sharp & Dohme LLC | $15.26 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.89 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.87 | 2019 | |
| Horizon Therapeutics Plc | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Silberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.